FX.co ★ Axsome Therapeutics, Inc. Q2 Loss Increases, Misses Estimates

Axsome Therapeutics, Inc. (AXSM) reported a widening loss for its second quarter, exceeding the prior year's figures and falling short of Wall Street's expectations.

The company posted a net loss of $79.345 million, or $1.67 per share, compared to a loss of $67.170 million, or $1.54 per share, in the same quarter last year.

According to data compiled by Thomson Reuters, analysts had, on average, anticipated a smaller loss of $1.33 per share. These estimates typically do not account for special items.

Despite the increasing loss, Axsome Therapeutics saw a significant revenue growth of 86.7%, reaching $87.166 million, up from $46.700 million in the previous year.

Summary of Axsome Therapeutics, Inc.'s second quarter (GAAP):

- Net Loss: $79.345 million, compared to $67.170 million last year.

- Earnings Per Share (EPS): -$1.67, compared to -$1.54 last year.

- Revenue: $87.166 million, compared to $46.700 million last year.